180 related articles for article (PubMed ID: 12567413)
1. Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk.
Armstrong K; Weber B; Stopfer J; Calzone K; Putt M; Coyne J; Schwartz JS
Am J Med Genet A; 2003 Mar; 117A(2):154-60. PubMed ID: 12567413
[TBL] [Abstract][Full Text] [Related]
2. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
Armstrong K; Micco E; Carney A; Stopfer J; Putt M
JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
[TBL] [Abstract][Full Text] [Related]
3. Interest in BRCA1/2 testing in a primary care population.
Armstrong K; Weber B; Ubel PA; Guerra C; Schwartz JS
Prev Med; 2002 Jun; 34(6):590-5. PubMed ID: 12052018
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Hall MJ; Reid JE; Wenstrup RJ
Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
[TBL] [Abstract][Full Text] [Related]
6. Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations.
Kelly K; Leventhal H; Marvin M; Toppmeyer D; Much J; Dermody J; Baran J; Schwalb M
Genet Test; 2004; 8(2):139-47. PubMed ID: 15345111
[TBL] [Abstract][Full Text] [Related]
7. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
Hull LE; Haas JS; Simon SR
Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
[TBL] [Abstract][Full Text] [Related]
8. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.
Wevers MR; Schmidt MK; Engelhardt EG; Verhoef S; Hooning MJ; Kriege M; Seynaeve C; Collée M; van Asperen CJ; Tollenaar RA; Koppert LB; Witkamp AJ; Rutgers EJ; Aaronson NK; Rookus MA; Ausems MG
Fam Cancer; 2015 Sep; 14(3):355-63. PubMed ID: 25700605
[TBL] [Abstract][Full Text] [Related]
9. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
[TBL] [Abstract][Full Text] [Related]
10. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
Levy DE; Byfield SD; Comstock CB; Garber JE; Syngal S; Crown WH; Shields AE
Genet Med; 2011 Apr; 13(4):349-55. PubMed ID: 21358336
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
[TBL] [Abstract][Full Text] [Related]
12. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.
Høberg-Vetti H; Eide GE; Siglen E; Listøl W; Haavind MT; Hoogerbrugge N; Bjorvatn C
Acta Oncol; 2019 Feb; 58(2):175-181. PubMed ID: 30334464
[TBL] [Abstract][Full Text] [Related]
13. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
[TBL] [Abstract][Full Text] [Related]
14. Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
Steffen LE; Du R; Gammon A; Mandelblatt JS; Kohlmann WK; Lee JH; Buys SS; Stroup AM; Campo RA; Flores KG; Vicuña B; Schwartz MD; Kinney AY
Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1772-1780. PubMed ID: 28971986
[No Abstract] [Full Text] [Related]
15. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
17. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
[TBL] [Abstract][Full Text] [Related]
18. Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
McGuinness JE; Trivedi MS; Silverman T; Marte A; Mata J; Kukafka R; Crew KD
Cancer Genet; 2019 Jun; 235-236():72-76. PubMed ID: 31078448
[TBL] [Abstract][Full Text] [Related]
19. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV
Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216
[TBL] [Abstract][Full Text] [Related]
20. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer.
Susswein LR; Skrzynia C; Lange LA; Booker JK; Graham ML; Evans JP
J Clin Oncol; 2008 Jan; 26(1):32-6. PubMed ID: 18165638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
